ChampioNIR (peripheral stent)

2024: Product Announcement

In early October 2024, Medinol introduced the peripheral drug-eluting stent ChampioNIR, designed for rapid and targeted drug delivery.

The first successful stent implantation was performed by Dr. Gerard S. Goh and Dr. Todur Vasudevan of the Alfred Hospital in Melbourne, Australia. According to the company, the new stent represents a "revolutionary achievement" in the development of effective and durable peripheral drug-eluting stents.

𝓲

Medinol.com

Medinol, based in Tel Aviv, Israel, has developed the ChampioNIR stent to improve both patient outcomes and the success of implantation procedures. The ChampioNIR stent is a first-of-its-kind hybrid design with radial support provided by the metal component of the stent. In turn, the bioresorbable polymer network forms a flexible and durable longitudinal structure of the stent, allowing it to be installed in complex vessels.

ChampioNIR provides a unique type of drug release that penetrates the blood throughout the cylindrical part of the stent. This approach enhances diffusion and allows the drug to be delivered at a therapeutic dosage over a long period of time.

Medinol is pleased to present the results of many years of research and development in the field of stents of a new design, specially created to solve complex clinical problems facing doctors during vascular interventions, "said Dr. Yoram Richter, CEO of Medinol. It is known that Medinol is already conducting the first human study of a new stent in Australia and the United States. In total, the company plans to attract 30 patients from 7 clinical centers[1]

Notes